Red Propolis as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Chronic Kidney Disease
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 40
- 试验地点
- 1
研究概览
简要总结
The objective of this study is to evaluate the effects of red propolis on inflammation and oxidative stress in patients with chronic kidney disease on conservative management.
详细描述
Chronic kidney disease (CKD) is associated with chronic systemic inflammation and oxidative stress, which contribute to disease progression and adverse outcomes. Red propolis is a natural substance rich in bioactive compounds with potential anti-inflammatory and antioxidant effects. Clinical evidence on its use in CKD patients is limited, and no studies have evaluated its impact on gene expression related to inflammation and oxidative stress. This randomized, double-blind, placebo-controlled trial will assess the effects of alcoholic extract of red propolis (200 mg/day for 8 weeks) on inflammatory and oxidative stress markers in patients with CKD stages 3-5 under conservative management. Blood samples will be collected at baseline and after intervention to evaluate routine biochemical parameters, inflammatory and oxidative stress markers, and gene expression. Nutritional status and dietary intake will also be assessed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Health Services Research
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients with CKD stages 3-5 under conservative management
排除标准
- •pregnant,
- •lactating,
- •patients using antibiotics and antioxidant supplements in the last three months
- •patients with autoimmune and infectious diseases,
- •patients with cancer, liver disease, and AIDS
研究组 & 干预措施
Red Propolis Group
Patients with chronic kidney disease will receive capsules containing 200mg of red propolis / day for two months.
干预措施: Red Propolis (Dietary Supplement)
Placebo Group
Patients with chronic kidney disease will receive capsules containing 200mg of placebo/ day for two months.
干预措施: Placebo Control (Other)
